Table 1. overview of studies in the pooled analysis (N = 2417).
| Study/year | Phase | Primary endpoint | Treatment regimen | No.of patients | CR+PR (%) | PFS, mo | OS, mo | 1- Year SR (%) | Jadad score |
| Lynch T.J.et al 2009 | II | ORR | Erlotinib/Bortezomib | 25 | 9 | 1.3 | 8.5 | 40 | 3 |
| Erlotinib | 25 | 16 | 2.7 | 7.3 | 30 | ||||
| Bennouna J. et al 2010 | II | NR | Erlotinib/Everolimus | 66 | 12.1 | 2.9 | NR | NR | 3 |
| Erlotinib | 67 | 10.4 | 2.0 | NR | NR | ||||
| HerBst, Roy S. et al 2011 | III | OS | Erlotinib/bevacizumab | 319 | 13 | 3.4 | 9.3 | 42.1 | 5 |
| Erlotinib/placebo | 317 | 6 | 1.7 | 9.2 | 40.7 | ||||
| Sequist L.V. et al. 2011 | II | PFS | Erlotinib/tivantinib | 84 | 10 | 3.8 | 8.5 | NR | 5 |
| Erlotinib/placebo | 83 | 7 | 2.3 | 6.9 | NR | ||||
| Spigel D.R. et al. 2011 | II | ORR and PFS | Erlotinib/sorafenib | 112 | 8 | 3.38 | 7.62 | NR | 5 |
| Erlotinib/placebo | 56 | 11 | 1.94 | 7.23 | NR | ||||
| Ramalingam S.S. et al. 2011 | II | PFS | Erlotinib/R1507(IGF-1R)weekly | 57 | 8.8 | 1.6 | 8.1 | NR | 5 |
| Erlotinib/R1507(IGF-1R)Q 3 weekly | 57 | 7 | 2.7 | 12.1 | NR | ||||
| Erlotinib/placebo | 57 | 8.8 | 1.5 | 8.1 | NR | ||||
| Scagliotti G.V. et al. 2011 | III | OS | Erlotinib/sunitinib | 480 | 10.6 | 3.6 | 9.0 | NR | 5 |
| Erlotinib/placebo | 480 | 6.9 | 2.0 | 8.5 | NR | ||||
| Witta S.E.et al. 2012 | II | OS | Erlotinib/Entinostat | 67 | 3.0 | 1.97 | 8.9 | NR | 5 |
| Erlotinib/placebo | 65 | 9.2 | 1.88 | 6.7 | NR |
Abbreviations: OS: overall survival; ORR: overall response rate; PFS: progression-free survival; CR: complete response; PR: partial response; 1-year SR: 1-year survival rate; NR: not reported.